Civitas Therapeutics to Present at JMP Securities Healthcare Conference

  Civitas Therapeutics to Present at JMP Securities Healthcare Conference

JMP Securities Healthcare Conference 2013

Business Wire

CHELSEA, Mass. -- July 2, 2013

Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in
Parkinson’s disease that leverages the ARCUS^(TM) respiratory delivery
platform, today announced that Glenn Batchelder, President and Chief Executive
Officer, will present a corporate update at the JMP Securities Healthcare
Conference in New York City on Tuesday, July 9, 2013 at 4:30 p.m. (EDT).

About Civitas Therapeutics

Civitas Therapeutics is a privately-held biopharmaceutical company focused on
developing a robust pipeline of inhaledtherapeutics with the
clinically-proven ARCUS^(TM) dry powder pulmonary delivery platform. The
company’s lead program, CVT-301, is being developed as adjunctive PRN therapy
to provide Parkinson’s disease patients with rapid and reliable relief from
intermittent debilitating motor fluctuations (OFF episodes). OFF episodes
result from the unreliability of current medications -- a problem impacting
about half of all Parkinson’s disease patients. Civitas recently announced
positive results for CVT-301 in a Phase 2 dose-ranging study. The Company’s
pipeline also includes products for respiratory disease, central nervous
system disorders and infectious disease.

The ARCUS^(TM) platform is a proprietary dry powder and device combination
with a unique ability to deliver a large, precise dose independent of
inspiratory flow rate from a simple, breath actuated device and is protected
by a large intellectual property estate. The technology has successfully
delivered more than one million doses to patients and the manufacturing
technology has been scaled to accommodate a significant commercial launch. The
Company is financed by leading investors including Canaan Partners, Fountain
Healthcare Partners, Longitude Capital and Alkermes plc. For further
information on Civitas, please visit www.civitastherapeutics.com.

Contact:

Civitas Therapeutics
Stephanie Gillis, 617-660-4121
sgillis@civitastherapeutics.com
 
Press spacebar to pause and continue. Press esc to stop.